Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...
Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this year.
people with diabetes announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose ...
Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with ...
RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for ...
RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for ...
RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for ...
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback